Singapore-based biotech startup BioactivX nets $1.4m seed led by Cocoon Capital
- ByStartupStory | November 11, 2025
BioactivX, a Singapore-based biotech startup specializing in advanced wound care solutions, has successfully raised $1.4 million in seed funding. The round was led by Cocoon Capital, a prominent early-stage venture capital firm focused on the Southeast Asia ecosystem, marking a significant milestone in the startup’s journey to innovate in tissue regeneration and reduce healthcare costs.
BioactivX’s flagship product, Bioactiv™ Matrix, utilizes synthetic biomaterials and proprietary peptide technology designed to accelerate wound healing, minimize scarring, and reduce infection risks. Unlike traditional treatments that rely on animal collagen or growth factors, BioactivX offers a synthetic, cell-free solution that has demonstrated success in clinical settings, including deep dermal burns and chronic wounds such as foot ulcers and surgical wounds. Patients treated with BioactivX products have shown enhanced healing outcomes without scars post-recovery.
The seed capital will be utilized to accelerate product development, expand clinical trials, and scale manufacturing capabilities to meet increasing demand from hospitals and wound care centers worldwide. Given Singapore’s status as a growing biotech and life sciences hub, BioactivX is well-positioned to leverage local resources, research institutions, and strategic partnerships to advance its technologies.
Founder and CEO Peili Teo emphasizes the startup’s commitment to high-quality, science-driven innovation aimed at transforming the global wound care market. “Our synthetic biomaterial is a game-changer, delivering superior healing results while addressing supply chain and ethical concerns associated with animal-derived products,” Teo said.
With healthcare systems globally facing heightened pressures to improve patient outcomes and reduce treatment costs, BioactivX’s technology aligns perfectly with shifting trends towards regenerative medicine and sustainable healthcare solutions.
The investment by Cocoon Capital not only provides the financial backing needed for BioactivX to accelerate its growth but also brings extensive industry expertise and network support, crucial for navigating regulatory pathways and expanding in international markets.
In summary, BioactivX’s $1.4 million seed funding led by Cocoon Capital fuels its mission to revolutionize wound care through cutting-edge synthetic peptide biomaterials. Positioned in Singapore’s vibrant biotech ecosystem, the startup is on track to deliver innovative medical solutions that improve healing, reduce scarring, and lower healthcare costs globally.
Follow Startup Story
Related Posts
